Mounjaro & Rybelsus (Type 2 Diabetes Medication)

Mounjaro & Rybelsus (Type 2 Diabetes Medication)

As part of our comprehensive care for Type 2 diabetes and blood glucose management, Tokyo Relife Clinic prescribes advanced incretin-based therapies: Mounjaro (Tirzepatide) and Rybelsus (Semaglutide).

These medications work by naturally stimulating insulin secretion to help maintain healthy blood glucose levels. They may also reduce appetite and contribute to weight loss. For this reason, they have attracted global attention in the field of medical weight management.

Mounjaro vs Rybelsus: What"s the Difference?

Rybelsus (oral Semaglutide)

A once-daily oral tablet taken by mouth. It"s often chosen by patients who prefer to avoid self‑injection but still want incretin‑based support for Type 2 diabetes and blood glucose management.

Mounjaro (Tirzepatide)

A once‑weekly subcutaneous injection. Because it acts on two hormones (GIP and GLP‑1), clinical studies have reported particularly strong effects on blood glucose control and weight management compared with traditional GLP‑1–only therapies.

For a side‑by‑side overview of their key features, please see the comparison table below.

※ All prescriptions for Mounjaro and Rybelsus at Tokyo Relife Clinic are self-pay treatments (not covered by Japan"s public health insurance).

Stem Cell Therapy for Diabetes: Beyond Temporary Medication

While Rybelsus and Mounjaro are highly effective for blood glucose management, they remain symptom-based treatments that assist insulin secretion only while the medication is actively being taken — typically requiring lifelong, continuous use.

At Tokyo Relife Clinic, we offer a more advanced option addressing the root causes: Stem Cell Therapy for Diabetes.

This regenerative approach utilizes the growth factors secreted by stem cells (paracrine effect) and their potent anti-inflammatory properties to support the repair of pancreatic β-cells damaged by chronic high blood sugar. Furthermore, it aims to improve insulin resistance at a systemic level, helping to restore your body"s natural ability to control blood glucose.

Rather than relying solely on ongoing medication, the goal is to target the underlying cellular decline and help restore your body"s natural function.

A Registered Medical Institution

Tokyo Relife Clinic provides this treatment as a registered provider under Japan"s Act on the Safety of Regenerative Medicine, with our treatment plan officially accepted by the Ministry of Health, Labour and Welfare.

If you are seeking a more fundamental approach to managing your diabetes, please see below for complete details.

・PB3240266: Regenerative medicine using autologous adipose-derived stem cells for glucose metabolism abnormalities

Important Notice: Off-Label Use for Weight Management

If you are requesting Mounjaro or Rybelsus for weight management (medical diet) rather than Type 2 diabetes, this constitutes off-label use of unapproved indications under Japan"s Pharmaceuticals and Medical Devices Act. Please carefully review the following information:

1. Unapproved Indication Status While these medications are domestically approved for Type 2 diabetes, their prescription specifically for obesity treatment or weight management is an unapproved, off-label use in Japan.

2. Procurement Route We procure genuine, domestically approved medications (for Type 2 diabetes) directly from authorized pharmaceutical wholesalers in Japan.

3. Availability of Approved Alternatives Medications explicitly approved for obesity treatment in Japan, such as Zepbound and Wegovy, do exist.

4. International Safety & Approval Status

• Tirzepatide (Mounjaro): Approved by the US FDA for obesity treatment in November 2023.
• Rybelsus (Oral Semaglutide): Not approved internationally for obesity treatment (Note: injectable forms of the same active ingredient are approved).
• Safety Profile: Both medications carry risks of serious side effects, including hypoglycemia, acute pancreatitis, and severe gastrointestinal disorders.

5. Exclusion from Public Relief Systems When these medications are used off-label for weight management, they are excluded from Japan"s Relief System for Sufferers from Adverse Drug Reactions. In the unlikely event of severe side effects, you will not be eligible for public financial compensation or relief measures. Please fully understand this condition before proceeding with treatment.